CA2249390C - Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor - Google Patents

Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor Download PDF

Info

Publication number
CA2249390C
CA2249390C CA002249390A CA2249390A CA2249390C CA 2249390 C CA2249390 C CA 2249390C CA 002249390 A CA002249390 A CA 002249390A CA 2249390 A CA2249390 A CA 2249390A CA 2249390 C CA2249390 C CA 2249390C
Authority
CA
Canada
Prior art keywords
seq
peptide
amino acid
type
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002249390A
Other languages
English (en)
French (fr)
Other versions
CA2249390A1 (en
Inventor
Craig L. Slingluff
Donald F. Hunt
Jeffrey Shabanowitz
Andrea L. Cox
Victor H. Engelhard
David Kittlesen
Jonathan Skipper
Ronald C. Hendrikson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia Patent Foundation filed Critical University of Virginia Patent Foundation
Publication of CA2249390A1 publication Critical patent/CA2249390A1/en
Application granted granted Critical
Publication of CA2249390C publication Critical patent/CA2249390C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0055Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/46449Melanoma antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/46449Melanoma antigens
    • A61K39/464492Glycoprotein 100 [Gp100]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002249390A 1996-03-19 1997-03-17 Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor Expired - Fee Related CA2249390C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1397296P 1996-03-19 1996-03-19
US60/013,972 1996-03-19
US2762796P 1996-10-04 1996-10-04
US60/027,627 1996-10-04
PCT/US1997/004958 WO1997034613A1 (en) 1996-03-19 1997-03-17 Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor

Publications (2)

Publication Number Publication Date
CA2249390A1 CA2249390A1 (en) 1997-09-25
CA2249390C true CA2249390C (en) 2007-12-18

Family

ID=26685490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002249390A Expired - Fee Related CA2249390C (en) 1996-03-19 1997-03-17 Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor

Country Status (4)

Country Link
EP (1) EP0921805A4 (de)
AU (1) AU712820B2 (de)
CA (1) CA2249390C (de)
WO (1) WO1997034613A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763071B1 (fr) * 1997-05-07 2003-05-16 Centre Nat Rech Scient Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
EP1161147A4 (de) * 1998-12-24 2002-07-24 New York Medical College Peptid-mimetika zur behandlung von krankheiten
CA2362295A1 (en) * 1999-02-11 2000-08-17 Genzyme Corporation Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
EP1964573B1 (de) 1999-10-22 2014-11-26 Aventis Pasteur Limited Verfahren zur Induzierung und/oder Verbesserung einer Immunreaktion auf Tumorantigene
AU1440601A (en) * 1999-10-29 2001-05-14 Argonex Pharmaceuticals, Inc. Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP1355926A2 (de) * 2000-05-31 2003-10-29 Genzyme Corporation Therapeutische verbindungen für eierstockkrebs
AU2002249917A1 (en) * 2001-01-04 2002-08-12 Yale University Induction of immune responses to isoaspartyl-modified antigens
CN1313617C (zh) 2001-11-07 2007-05-02 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
WO2009110873A2 (en) 2007-12-05 2009-09-11 The Gov. Of The Usa, As Represented By The Secretary Dept. Of Health & Human Services Improved viral protein quantification and vaccine quality control therewith

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006916B1 (de) * 1977-09-28 1981-07-08 National Research Development Corporation MHC-Antigene enthaltende immunologische Präparate und deren Herstellung
AU679965B2 (en) * 1992-12-22 1997-07-17 Ludwig Institute For Cancer Research Methods for detection and treatment of individuals having abnormal cells expressing HLA-A2/tyrosinase peptide antigens
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
AU735459B2 (en) * 1997-01-30 2001-07-12 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor

Also Published As

Publication number Publication date
AU2424397A (en) 1997-10-10
CA2249390A1 (en) 1997-09-25
AU712820B2 (en) 1999-11-18
WO1997034613A1 (en) 1997-09-25
EP0921805A4 (de) 2002-06-26
EP0921805A1 (de) 1999-06-16

Similar Documents

Publication Publication Date Title
US20220072113A1 (en) Antigen specific multi epitope vaccines
US8067529B2 (en) Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
US5662907A (en) Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
KR101386827B1 (ko) 인간 백혈구 항원(hla) 유형 ii 분자에 불규칙적으로 결합하는 종양 관련 펩티드
US7157091B1 (en) MAGE-A1 peptides presented by HLA class II molecules
AU701531B2 (en) Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
AU6042099A (en) Mage-a3 peptides presented by hla class ii molecules
JP2001516579A (ja) Hlaクラスii分子により提示されるmage−3ペプチド
US6558671B1 (en) Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
CA2249390C (en) Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
WO1998033810A9 (en) Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor
US7019112B1 (en) Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
US20070280939A1 (en) Prostatic Acid Phosphatase Antigens
US6716809B1 (en) Mage-A3 peptides presented by HLA class molecules
WO2001016320A1 (en) Isolated nona and decapeptides which bind to hla molecules, and the use thereof
US20060009393A1 (en) Immunogenic epitopes for fibroblast growth factors 5 (FGF-5)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed